Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 9/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060609 | 0.78 | APEX1 (0.42) | PDK2RAB9AALDH1A1KDM4EAPEX1 | |
| SCHEMBL24314006 | 0.76 | KMT2A (0.44) | PDK2APEX1THRBTDP1 | |
| SCHEMBL25135052 | 0.71 | PDK2 (0.41) | PDK2RAB9AALDH1A1KDM4ETHRB | |
| SCHEMBL24314130 | 0.70 | PDK2 (0.38) | PDK2ALDH1A1APEX1THRBTDP1 | |
| SCHEMBL24314083 | 0.67 | PDK2 (0.46) | PDK2KDM4ETHRBTDP1 | |
| SCHEMBL17186642 | 0.67 | PDK2 (0.38) | PDK2ALDH1A1KDM4EAPEX1THRB | |
| SCHEMBL3782236 | 0.67 | APEX1 (0.48) | PDK2RAB9AALDH1A1KDM4EAPEX1 | |
| SCHEMBL6316881 | 0.66 | PDK2 (0.50) | PDK2KDM4EAPEX1THRBTDP1 | |
| SCHEMBL2320531 | 0.66 | PDK2 (0.50) | PDK2KDM4EAPEX1THRBTDP1 | |
| SCHEMBL29518493 | 0.66 | PDK2 (0.50) | PDK2KDM4EAPEX1THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2022076820-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | FABP5, FABP1, FABP4 | PDK2 3044/4885RAB9A 2980/4885ALDH1A1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.